<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260256</url>
  </required_header>
  <id_info>
    <org_study_id>53563</org_study_id>
    <nct_id>NCT04260256</nct_id>
  </id_info>
  <brief_title>A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors</brief_title>
  <official_title>A Pilot Study of Using [18F]F AraG PET Imaging to Evaluate the Immunological Response to Checkpoint Inhibitor Therapy (CkIT) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellSight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CellSight Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients with advanced solid tumors will undergo [18F]F AraG PET/CT imaging to&#xD;
      assess for changes in tracer uptake following treatment with CkIT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 40 patients will be recruited to participate in this study. Two (2) target lesions per&#xD;
      patient will be selected for radiomics and biopsy. Both lesions will be assessed for [18F]F&#xD;
      AraG uptake before and after CkIT. Only one lesion will be biopsied twice (once before and&#xD;
      once after CkIT treatment close to the time of imaging), and the other lesion will not be&#xD;
      manipulated and used as a control.&#xD;
&#xD;
      There will be a pre therapy scan [18F]F AraG which will be administered anytime within a 14&#xD;
      day period prior to the initial Day 1 CkIT administration. There will also be a post therapy&#xD;
      scan which will be performed within 3 to 6 weeks after the initial CkIT dose. The timing of&#xD;
      the second [18F]F AraG scans may be altered based on preliminary results from the initial&#xD;
      patient scan results, and could be obtained during the first 2 weeks after initiation of&#xD;
      therapy.&#xD;
&#xD;
      The investigators will compare the [18F]F AraG activity (based on development of tumoral&#xD;
      volumes of interest (VOIs) pre and post CkIT in both lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate change in [18F]F AraG signal following CkIT therapy with change in level of T cell infiltration in tumor biopsies</measure>
    <time_frame>24 Months</time_frame>
    <description>Pre and post CkIT biopsies of the same tumor lesion will be performed an analyze T-cell tumor infiltration, this will be correlated to [18F]F-AraG PET signal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Correlate change in [18F]F AraG uptake signal in tumor lesions with clinical benefit rate (defined as Complete Response (CR) + Partial Response (PR) + stable disease (SD) &gt; 4 months) using iRECIST criteria</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Correlate change in [18F]F AraG signal in lung and GI tract with the occurrence of Grade 3 or 4 immune related adverse events.</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Correlate Tracer Uptake to TCell Tumor Infiltration &amp; CkIT Benefit</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]F-AraG</intervention_name>
    <description>[18F]F AraG injection and PET Scan Two tumor biopsies of single lesion</description>
    <other_name>VisAcT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solid tumor with planned CkIT&#xD;
&#xD;
          -  Must be &gt;18 years old&#xD;
&#xD;
          -  Signed Informed Consent Form&#xD;
&#xD;
          -  Patient must have two qualifying lesions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carina Mari Aparici, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Mittra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shivaani Kummar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LIbby Mirande</last_name>
    <phone>503 494 4740</phone>
    <email>jenselib@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Risa Jiron</last_name>
      <phone>650-736-1598</phone>
      <email>rjiron@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Carina Mari Aparici, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Libby Mirande</last_name>
      <phone>503-494-4740</phone>
      <email>jenselib@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Mittra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

